[go: up one dir, main page]

BG107697A - Ep4 receptor selective agonists in the treatment of osteoporosis - Google Patents

Ep4 receptor selective agonists in the treatment of osteoporosis

Info

Publication number
BG107697A
BG107697A BG107697A BG10769703A BG107697A BG 107697 A BG107697 A BG 107697A BG 107697 A BG107697 A BG 107697A BG 10769703 A BG10769703 A BG 10769703A BG 107697 A BG107697 A BG 107697A
Authority
BG
Bulgaria
Prior art keywords
bone
directed
bone loss
selective agonists
osteoporosis
Prior art date
Application number
BG107697A
Other languages
Bulgarian (bg)
English (en)
Inventor
Kimberly O. Cameron
Bruce A. Lefker
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107697A publication Critical patent/BG107697A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG107697A 2000-11-27 2003-04-03 Ep4 receptor selective agonists in the treatment of osteoporosis BG107697A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
BG107697A true BG107697A (en) 2004-01-30

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107697A BG107697A (en) 2000-11-27 2003-04-03 Ep4 receptor selective agonists in the treatment of osteoporosis

Country Status (41)

Country Link
US (3) US6552067B2 (xx)
EP (1) EP1339678B1 (xx)
JP (2) JP3984164B2 (xx)
KR (1) KR20030053063A (xx)
CN (1) CN1476429A (xx)
AR (1) AR035074A1 (xx)
AT (1) ATE374182T1 (xx)
AU (1) AU2002210848A1 (xx)
BG (1) BG107697A (xx)
BR (1) BR0115687A (xx)
CA (1) CA2429850C (xx)
CY (1) CY1106976T1 (xx)
CZ (1) CZ20031257A3 (xx)
DE (1) DE60130675T2 (xx)
DK (1) DK1339678T3 (xx)
EA (1) EA200300379A1 (xx)
EC (1) ECSP034623A (xx)
EE (1) EE200300246A (xx)
ES (1) ES2291361T3 (xx)
GT (2) GT200100238AA (xx)
HN (1) HN2001000266A (xx)
HU (1) HUP0400807A2 (xx)
IL (1) IL155368A0 (xx)
IS (1) IS6775A (xx)
MA (1) MA26961A1 (xx)
MX (1) MXPA03004623A (xx)
NO (1) NO20032360L (xx)
NZ (1) NZ525164A (xx)
OA (1) OA12533A (xx)
PA (1) PA8533901A1 (xx)
PE (1) PE20020637A1 (xx)
PL (1) PL362030A1 (xx)
PT (1) PT1339678E (xx)
SI (1) SI1339678T1 (xx)
SK (1) SK5562003A3 (xx)
SV (1) SV2003000746A (xx)
TN (1) TNSN01166A1 (xx)
TW (1) TW200424170A (xx)
UY (1) UY27038A1 (xx)
WO (1) WO2002042268A2 (xx)
ZA (1) ZA200302803B (xx)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1339678T1 (sl) * 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
AU2002328855B2 (en) * 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
KR100826866B1 (ko) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
AU2003233731A1 (en) * 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1513589B1 (en) * 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
EP1581503A4 (en) 2002-11-08 2007-07-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
WO2004078103A2 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1663987B1 (en) 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
CA2549935A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
CA2586752A1 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
CN101133037B (zh) * 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
CA2688897A1 (en) * 2007-05-23 2008-11-23 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
EP2320906B1 (en) * 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
TWI555744B (zh) * 2010-03-08 2016-11-01 Kaken Pharma Co Ltd Novel EP4 agonists
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
BR112013021035A2 (pt) 2011-02-17 2016-10-11 Allergan Inc composições e métodos de reposição de tecido macio aperfeiçoados
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
CA2879506C (en) * 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
EP2970234B1 (en) 2013-03-15 2018-07-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
BR112015023080A2 (pt) * 2013-03-15 2017-07-18 Cayman Chemical Co Inc composto, composição farmacêutica, e, método para tratamento de doenças
AU2014290512A1 (en) * 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
TR201905436T4 (tr) 2014-06-06 2019-05-21 Allergan Inc Terapötik bileşikler olarak yeni ep4 agonistleri.
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CA2988523A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
CN109072186B (zh) * 2016-03-04 2023-06-23 莱兰斯坦福初级大学评议会 利用前列腺素e2进行肌肉再生的组合物和方法
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
ES2929799T3 (es) 2017-12-25 2022-12-01 Asahi Kasei Pharma Corp Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (xx) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
WO2000021532A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
WO2001046140A1 (en) * 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
IL141120A0 (en) * 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
SI1339678T1 (sl) * 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
MXPA03004623A (es) 2003-09-05
CA2429850A1 (en) 2002-05-30
US7192979B2 (en) 2007-03-20
KR20030053063A (ko) 2003-06-27
UY27038A1 (es) 2002-07-31
JP2004521869A (ja) 2004-07-22
EP1339678A2 (en) 2003-09-03
JP3984164B2 (ja) 2007-10-03
IL155368A0 (en) 2003-11-23
ZA200302803B (en) 2004-04-13
HN2001000266A (es) 2002-01-30
WO2002042268A2 (en) 2002-05-30
OA12533A (en) 2006-06-05
TNSN01166A1 (fr) 2005-11-10
MA26961A1 (fr) 2004-12-20
US20020065308A1 (en) 2002-05-30
SK5562003A3 (en) 2004-08-03
PL362030A1 (en) 2004-10-18
ECSP034623A (es) 2003-07-25
WO2002042268A3 (en) 2002-07-25
EE200300246A (et) 2003-10-15
SI1339678T1 (sl) 2007-12-31
DK1339678T3 (da) 2008-02-04
NO20032360L (no) 2003-07-23
SV2003000746A (es) 2003-01-13
IS6775A (is) 2003-04-10
US20030149086A1 (en) 2003-08-07
NZ525164A (en) 2005-04-29
TW200424170A (en) 2004-11-16
EP1339678B1 (en) 2007-09-26
ATE374182T1 (de) 2007-10-15
US6552067B2 (en) 2003-04-22
BR0115687A (pt) 2003-09-09
AR035074A1 (es) 2004-04-14
PT1339678E (pt) 2007-11-30
PE20020637A1 (es) 2002-07-18
CY1106976T1 (el) 2012-09-26
DE60130675T2 (de) 2008-01-24
EA200300379A1 (ru) 2003-08-28
GT200100238A (es) 2002-06-26
AU2002210848A1 (en) 2002-06-03
CA2429850C (en) 2008-12-30
JP2007197467A (ja) 2007-08-09
DE60130675D1 (de) 2007-11-08
CZ20031257A3 (cs) 2004-04-14
US6747054B2 (en) 2004-06-08
CN1476429A (zh) 2004-02-18
GT200100238AA (es) 2004-05-12
ES2291361T3 (es) 2008-03-01
US20040259921A1 (en) 2004-12-23
NO20032360D0 (no) 2003-05-26
HUP0400807A2 (hu) 2004-07-28
PA8533901A1 (es) 2002-11-28

Similar Documents

Publication Publication Date Title
BG107697A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
MY141476A (en) 5ht2c receptor modulators
TW200609235A (en) Tetraazabenzo[e]azulene derivatives and analogs thereof
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
BR9307825A (pt) Composição contendo fosfato de cálcio processo aperfeiçoado para a preparação da mesma e de um cimento de fosfato de cálcio fosfato tetracálcico conjunto de materiais precursores de composição contendo fosfato de cálcio e polpa
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
NZ520624A (en) 1,2,3,4-tetrahydroisoquinoline derivatives
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
PL370373A1 (en) Substituted piperidines as modulators of the melanocortin receptor
MXPA04000454A (es) Derivados de 2-pirrolidona como agonistas de prostanoides.
AP9801269A0 (en) Prostaglandin agonists.
CA2334257A1 (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
DE50312414D1 (de) Kompositmaterialien aus calciumverbindungen und glucuronsäurehaltigen polysacchariden
PL375163A1 (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa
CR6952A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
MY135292A (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200503793A (en) A composition in the form of solid body, its preparation process and uses thereof as bone filler